Initial Therapeutic Approach with Pembrolizumab in Synchronous Multiple Cancers, Including Non-Small Cell Lung Cancer, Highly Positive for Programmed Death-Ligand 1 Expression.

Koizumi, Tomonobu; Kanda, Shintaro; Kobayashi, Takashi; Iwasa, Yoh-Ichiro; Matsuo, Akemi

Koizumi, Tomonobu; Kanda, Shintaro; Kobayashi, Takashi; Iwasa, Yoh-Ichiro; Matsuo, Akemi.

Afiliación

Koizumi T; Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
Kanda S; Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
Kobayashi T; Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
Iwasa YI; Department of Otolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Matsuo A; Department of Pulmonary Medicine, Minami Nagano Iryou Center, Shinonoi Hospital, Nagano, Japan.

Chemotherapy ; 68(3): 160-167, 2023.

Article en En | MEDLINE | ID: mdl-36577398

Asunto(s)

Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Neoplasias Gástricas; Humanos; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/patología; Antígeno B7-H1/metabolismo; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/patología

Palabras clave

Double cancers; Immune checkpoint inhibitor; Multiple primary malignancy; Programmed death ligand-1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Chemotherapy Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google